Pharmacological and dietary agents for colorectal cancer chemoprevention: Effects on polyamine metabolism (Review)

Linsalata,Michele; Orlando,Antonella; Russo,Francesco

doi:10.3892/ijo.2014.2597

Pharmacological and dietary agents for colorectal cancer chemoprevention: Effects on polyamine metabolism (Review)

Authors:
- Michele Linsalata
- Antonella Orlando
- Francesco Russo
View Affiliations

Affiliations: Laboratory of Nutritional Pathophysiology, National Institute for Digestive Diseases, I.R.C.C.S. ‘S. de Bellis’ Via Turi 27, Castellana Grotte (Ba), I-70013, Italy
Published online on: August 14, 2014 https://doi.org/10.3892/ijo.2014.2597
Pages: 1802-1812

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoprevention is the long-term use of different chemical agents, both synthetic and natural, to prevent or delay the onset of disease. Since colorectal cancer has a significant environmental component, it is an ideal disease in which to evaluate the potential benefits of chemopreventive agents. The polyamines, spermine, spermidine and putrescine have been involved in almost all the steps of colorectal tumorigenesis. Consequently, polyamine biosynthesis and catabolism can be considered as promising targets for cancer chemoprevention. A variety of drug formulations have been tested for their efficacy in affecting polyamines in a strategy of colorectal cancer prevention. Different molecules, such as biosynthesis inhibitors and catabolism inducers, have been proposed alone or in combination with other drugs proved to diminish the colorectal cancer risk. Interestingly, also diet can play a role in cancer prevention by affecting polyamines. Several dietary components, such as probiotics or flavonoids, have been shown to affect the polyamine metabolic pathway in colorectal neoplastic tissue. On the other hand, the polyamines ingested with diet might contrast the above cited effects shown by both drugs and nutritional factors. It is, therefore, fundamental to acquire more data also on these aspects in view of an innovative approach to colorectal oncology. This review summarizes data on the role of polyamine metabolism in neoplastic transformation of colorectal mucosa and as possible target for colorectal cancer chemoprevention. Attention will be focused on the influence of drugs and nutritional factors on polyamine metabolism, as well as the role played by dietary polyamines.

View Figures

View References

1	Surh YJ: Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768–780. 2003. View Article : Google Scholar : PubMed/NCBI
2	Casero RA Jr and Marton LJ: Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases. Nat Rev Drug Discov. 6:373–390. 2007. View Article : Google Scholar : PubMed/NCBI
3	Ramani D, De Bandt JP and Cynober L: Aliphatic polyamines in physiology and diseases. Clin Nutr. 33:14–22. 2014. View Article : Google Scholar : PubMed/NCBI
4	Thomas T and Thomas TJ: Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 58:244–258. 2001. View Article : Google Scholar : PubMed/NCBI
5	Rothenburg S, Koch-Nolte F, Rich A and Haag F: A polymorphic dinucleotide repeat in the rat nucleolin gene forms Z-DNA and inhibits promoter activity. Proc Natl Acad Sci USA. 98:8985–8990. 2001. View Article : Google Scholar : PubMed/NCBI
6	Iacomino G, Picariello G and D’Agostino L: DNA and nuclear aggregates of polyamines. Biochim Biophys Acta. 1823:1745–1755. 2012. View Article : Google Scholar
7	Igarashi K and Kashiwagi K: Modulation of cellular function by polyamines. Int J Biochem Cell Biol. 42:39–51. 2010. View Article : Google Scholar : PubMed/NCBI
8	Pegg AE and Casero RA Jr: Current status of the polyamine research field. Methods Mol Biol. 720:3–35. 2011. View Article : Google Scholar : PubMed/NCBI
9	Pegg AE: Mammalian polyamine metabolism and function. IUBMB Life. 61:880–894. 2009. View Article : Google Scholar : PubMed/NCBI
10	Coffino P: Regulation of cellular polyamines by antizyme. Nat Rev Mol Cell Biol. 2:188–194. 2001. View Article : Google Scholar : PubMed/NCBI
11	Bachrach U: Polyamines and cancer: minireview article. Amino Acids. 26:307–309. 2004. View Article : Google Scholar : PubMed/NCBI
12	Linsalata M, Caruso MG, Leo S, Guerra V, D’Attoma B and Di Leo A: Prognostic value of tissue polyamine levels in human colorectal carcinoma. Anticancer Res. 22:2465–2469. 2002.PubMed/NCBI
13	Linsalata M, Giannini R, Notarnicola M and Cavallini A: Peroxisome proliferator-activated receptor gamma and spermidine/spermine N1-acetyltransferase gene expressions are significantly correlated in human colorectal cancer. BMC Cancer. 6:1912006. View Article : Google Scholar
14	Shantz LM and Levin VA: Regulation of ornithine decarboxylase during oncogenic transformation: mechanisms and therapeutic potential. Amino Acids. 33:213–223. 2007. View Article : Google Scholar
15	Erdman SH, Ignatenko NA, Powell MB, et al: APC-dependent changes in expression of genes influencing polyamine metabolism, and consequences for gastrointestinal carcinogenesis, in the Min mouse. Carcinogenesis. 20:1709–1713. 1999. View Article : Google Scholar
16	Casero RA and Pegg AE: Polyamine catabolism and disease. Biochem J. 421:323–338. 2009. View Article : Google Scholar : PubMed/NCBI
17	Palmer AJ and Wallace HM: The polyamine transport system as a target for anticancer drug development. Amino Acids. 38:415–422. 2010. View Article : Google Scholar : PubMed/NCBI
18	Thompson PA and Gerner EW: Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol. 3:369–382. 2009. View Article : Google Scholar : PubMed/NCBI
19	Pegg AE: Regulation of ornithine decarboxylase. J Biol Chem. 281:14529–14532. 2006. View Article : Google Scholar : PubMed/NCBI
20	Xiao L and Wang J-Y: Posttranscriptional regulation of gene expression in epithelial cells by polyamines. Methods Mol Biol. 720:67–79. 2011. View Article : Google Scholar : PubMed/NCBI
21	Ignatenko NA, Babbar N, Mehta D, Casero RA Jr and Gerner EW: Suppression of polyamine catabolism by activated Ki-ras in human colon cancer cells. Mol Carcinog. 39:91–102. 2004. View Article : Google Scholar : PubMed/NCBI
22	Linsalata M, Notarnicola M, Caruso MG, Di Leo A, Guerra V and Russo F: Polyamine biosynthesis in relation to K-ras and p-53 mutations in colorectal carcinoma. Scand J Gastroenterol. 39:470–477. 2004. View Article : Google Scholar : PubMed/NCBI
23	Notarnicola M, Linsalata M, Caruso MG, et al: Genetic and biochemical changes in colorectal carcinoma in relation to morphologic characteristics. Oncol Rep. 10:1987–1991. 2003.PubMed/NCBI
24	Babbar N and Gerner EW: Targeting polyamines and inflammation for cancer prevention. Recent Results Cancer Res. 188:49–64. 2011. View Article : Google Scholar : PubMed/NCBI
25	Seiler N: Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect Part 1 Selective enzyme inhibitors. Curr Drug Targets. 4:537–564. 2003.
26	Laukaitis CM and Gerner EW: DFMO: targeted risk reduction therapy for colorectal neoplasia. Best Pract Res Clin Gastroenterol. 25:495–506. 2011. View Article : Google Scholar : PubMed/NCBI
27	Gerner EW and Meyskens FL Jr: Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer. 4:781–792. 2004. View Article : Google Scholar : PubMed/NCBI
28	Love RR, Carbone PP, Verma AK, et al: Randomized phase I chemoprevention dose-seeking study of alpha-difluoromethylornithine. J Natl Cancer Inst. 85:732–737. 1993. View Article : Google Scholar : PubMed/NCBI
29	Levin VA, Uhm JH, Jaeckle KA, et al: Phase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N′-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiforme. Clin Cancer Res. 6:3878–3884. 2000.PubMed/NCBI
30	Leveque J, Burtin F, Catros-Quemener V, Havouis R and Moulinoux JP: The gastrointestinal polyamine source depletion enhances DFMO induced polyamine depletion in MCF-7 human breast cancer cells in vivo. Anticancer Res. 18:2663–2668. 1998.PubMed/NCBI
31	Meyskens FL Jr and Gerner EW: Development of difluoromethylornithine (DFMO) as a chemoprevention agent. Clin Cancer Res. 5:945–951. 1999.PubMed/NCBI
32	Gerner EW: Cancer chemoprevention locks onto a new polyamine metabolic target. Cancer Prev Res (Phila). 3:125–127. 2010. View Article : Google Scholar : PubMed/NCBI
33	Love RR, Jacoby R, Newton MA, et al: A randomized, placebo-controlled trial of low-dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiol Biomarkers Prev. 7:989–992. 1998.PubMed/NCBI
34	Meyskens FL Jr, Gerner EW, Emerson S, et al: Effect of alpha-difluoromethylornithine on rectal mucosal levels of polyamines in a randomized, double-blinded trial for colon cancer prevention. J Natl Cancer Inst. 90:1212–1218. 1998. View Article : Google Scholar
35	Flossmann E and Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet. 369:1603–1613. 2007. View Article : Google Scholar : PubMed/NCBI
36	Lawson KR, Ignatenko NA, Piazza GA, Cui H and Gerner EW: Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine. Cancer Epidemiol Biomarkers Prev. 9:1155–1162. 2000.PubMed/NCBI
37	Gerner EW and Meyskens FL Jr: Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation. Clin Cancer Res. 15:758–761. 2009. View Article : Google Scholar : PubMed/NCBI
38	Jacoby RF, Cole CE, Tutsch K, et al: Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos. Cancer Res. 60:1864–1870. 2000.
39	Ignatenko NA, Besselsen DG, Stringer DE, Blohm-Mangone KA, Cui H and Gerner EW: Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis. Nutr Cancer. 60(Suppl 1): 30–35. 2008. View Article : Google Scholar : PubMed/NCBI
40	Thompson PA, Wertheim BC, Zell JA, et al: Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma. Gastroenterology. 139:797–805. 2010. View Article : Google Scholar : PubMed/NCBI
41	Meyskens FL Jr, McLaren CE, Pelot D, et al: Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 1:32–38. 2008. View Article : Google Scholar
42	Zell JA, Pelot D, Chen WP, McLaren CE, Gerner EW and Meyskens FL: Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila). 2:209–212. 2009. View Article : Google Scholar : PubMed/NCBI
43	Zell JA, Ziogas A, Ignatenko N, et al: Associations of a polymorphism in the ornithine decarboxylase gene with colorectal cancer survival. Clin Cancer Res. 15:6208–6216. 2009. View Article : Google Scholar : PubMed/NCBI
44	Martinez ME, O’Brien TG, Fultz KE, et al: Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene. Proc Natl Acad Sci USA. 100:7859–7864. 2003. View Article : Google Scholar
45	Hubner RA, Muir KR, Liu JF, Logan RF, Grainge MJ and Houlston RS: Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention. Clin Cancer Res. 14:2303–2309. 2008. View Article : Google Scholar : PubMed/NCBI
46	Jell J, Merali S, Hensen ML, et al: Genetically altered expression of spermidine/spermine N1-acetyltransferase affects fat metabolism in mice via acetyl-CoA. J Biol Chem. 282:8404–8413. 2007. View Article : Google Scholar : PubMed/NCBI
47	Jacobs ET, Ahnen DJ, Ashbeck EL, et al: Association between body mass index and colorectal neoplasia at follow-up colonoscopy: a pooling study. Am J Epidemiol. 169:657–666. 2009. View Article : Google Scholar : PubMed/NCBI
48	Zell JA, Lin BS, Madson N, McLaren CE, Gerner EW and Meyskens FL: Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas. Cancer Causes Control. 23:1739–1744. 2012. View Article : Google Scholar : PubMed/NCBI
49	Wallace HM and Fraser AV: Inhibitors of polyamine metabolism: review article. Amino Acids. 26:353–365. 2004. View Article : Google Scholar : PubMed/NCBI
50	Niiranen K, Pietila M, Pirttila TJ, et al: Targeted disruption of spermidine/spermine N1-acetyltransferase gene in mouse embryonic stem cells. Effects on polyamine homeostasis and sensitivity to polyamine analogues. J Biol Chem. 277:25323–25328. 2002. View Article : Google Scholar : PubMed/NCBI
51	Battaglia V, DeStefano Shields C, Murray-Stewart T and Casero RA Jr: Polyamine catabolism in carcinogenesis: potential targets for chemotherapy and chemoprevention. Amino Acids. 46:511–519. 2014. View Article : Google Scholar : PubMed/NCBI
52	Seiler N: Thirty years of polyamine-related approaches to cancer therapy. Retrospect and prospect Part 2 Structural analogues and derivatives. Curr Drug Targets. 4:565–585. 2003.PubMed/NCBI
53	Wallace HM and Niiranen K: Polyamine analogues - an update. Amino Acids. 33:261–265. 2007. View Article : Google Scholar : PubMed/NCBI
54	Belting M, Borsig L, Fuster MM, et al: Tumor attenuation by combined heparan sulfate and polyamine depletion. Proc Natl Acad Sci USA. 99:371–376. 2002. View Article : Google Scholar : PubMed/NCBI
55	Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U and Faivre J: Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. European Cancer Prevention Organisation Study Group. Lancet. 356:1300–1306. 2000. View Article : Google Scholar : PubMed/NCBI
56	Delzenne NM and Williams CM: Prebiotics and lipid metabolism. Curr Opin Lipidol. 13:61–67. 2002. View Article : Google Scholar : PubMed/NCBI
57	Food and Agriculture Organization of the United Nations and World Health Organization. Probiotics in food: health and nutritional properties and guidelines for evaluation. Food and Agriculture Organization of the United Nations, World Health Organization; Rome: 2006
58	Boesten RJ and de Vos WM: Interactomics in the human intestine: Lactobacilli and Bifidobacteria make a difference. J Clin Gastroenterol. 42(Suppl 3): S163–S167. 2008. View Article : Google Scholar
59	Quigley EM: Gut bacteria in health and disease. Gastroenterol Hepatol (NY). 9:560–569. 2013.PubMed/NCBI
60	Riezzo G, Orlando A, D’Attoma B, et al: Randomised clinical trial: efficacy of Lactobacillus paracasei-enriched artichokes in the treatment of patients with functional constipation - a double-blind, controlled, crossover study. Aliment Pharmacol Ther. 35:441–450. 2012.
61	Valerio F, de Candia S, Lonigro SL, et al: Role of the probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes in influencing faecal bacteria and biochemical parameters in human subjects. J Appl Microbiol. 111:155–164. 2011.PubMed/NCBI
62	Sisto A and Lavermicocca P: Suitability of a probiotic Lactobacillus paracasei strain as a starter culture in olive fermentation and development of the innovative patented product ‘probiotic table olives’. Front Microbiol. 3:1742012.
63	Ishikawa H, Akedo I, Otani T, et al: Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer. 116:762–767. 2005. View Article : Google Scholar : PubMed/NCBI
64	Zeng H, Lazarova DL and Bordonaro M: Mechanisms linking dietary fiber, gut microbiota and colon cancer prevention. World J Gastrointest Oncol. 6:41–51. 2014. View Article : Google Scholar : PubMed/NCBI
65	Kulkarni N and Reddy BS: Inhibitory effect of Bifidobacterium longum cultures on the azoxymethane-induced aberrant crypt foci formation and fecal bacterial beta-glucuronidase. Proc Soc Exp Biol Med. 207:278–283. 1994.
66	Boleij A and Tjalsma H: Gut bacteria in health and disease: a survey on the interface between intestinal microbiology and colorectal cancer. Biol Rev Camb Philos Soc. 87:701–730. 2012. View Article : Google Scholar : PubMed/NCBI
67	Singh J, Rivenson A, Tomita M, Shimamura S, Ishibashi N and Reddy BS: Bifidobacterium longum, a lactic acid-producing intestinal bacterium inhibits colon cancer and modulates the intermediate biomarkers of colon carcinogenesis. Carcinogenesis. 18:833–841. 1997. View Article : Google Scholar
68	Di Marzio L, Russo FP, D’Alo S, et al: Apoptotic effects of selected strains of lactic acid bacteria on a human T leukemia cell line are associated with bacterial arginine deiminase and/or sphingomyelinase activities. Nutr Cancer. 40:185–196. 2001.
69	Linsalata M, Russo F, Berloco P, et al: The influence of Lactobacillus brevis on ornithine decarboxylase activity and polyamine profiles in Helicobacter pylori-infected gastric mucosa. Helicobacter. 9:165–172. 2004.
70	Famularo G, Perluigi M, Pieluigi M, Coccia R, Mastroiacovo P and De Simone C: Microecology, bacterial vaginosis and probiotics: perspectives for bacteriotherapy. Med Hypotheses. 56:421–430. 2001. View Article : Google Scholar : PubMed/NCBI
71	Orlando A, Messa C, Linsalata M, Cavallini A and Russo F: Effects of Lactobacillus rhamnosus GG on proliferation and polyamine metabolism in HGC-27 human gastric and DLD-1 colonic cancer cell lines. Immunopharmacol Immunotoxicol. 31:108–116. 2009.
72	Buts JP and De Keyser N: Effects of Saccharomyces boulardii on intestinal mucosa. Dig Dis Sci. 51:1485–1492. 2006.
73	Linsalata M, Russo F, Berloco P, et al: Effects of probiotic bacteria (VSL#3) on the polyamine biosynthesis and cell proliferation of normal colonic mucosa of rats. In Vivo. 19:989–995. 2005.
74	Matsumoto M and Benno Y: Consumption of Bifidobacterium lactis LKM512 yogurt reduces gut mutagenicity by increasing gut polyamine contents in healthy adult subjects. Mutat Res. 568:147–153. 2004.
75	Cederroth CR and Nef S: Soy, phytoestrogens and metabolism: A review. Mol Cell Endocrinol. 304:30–42. 2009. View Article : Google Scholar : PubMed/NCBI
76	Thompson LU, Robb P, Serraino M and Cheung F: Mammalian lignan production from various foods. Nutr Cancer. 16:43–52. 1991. View Article : Google Scholar : PubMed/NCBI
77	Albini A, Rosano C, Angelini G, et al: Exogenous hormonal regulation in breast cancer cells by phytoestrogens and endocrine disruptors. Curr Med Chem. 21:1129–1145. 2014. View Article : Google Scholar : PubMed/NCBI
78	Cassidy A: Potential risks and benefits of phytoestrogen-rich diets. Int J Vitam Nutr Res. 73:120–126. 2003. View Article : Google Scholar : PubMed/NCBI
79	Cotterchio M, Boucher BA, Manno M, Gallinger S, Okey A and Harper P: Dietary phytoestrogen intake is associated with reduced colorectal cancer risk. J Nutr. 136:3046–3053. 2006.PubMed/NCBI
80	Lechner D, Kállay E and Cross HS: Phytoestrogens and colorectal cancer prevention. Vitam Horm. 70:169–198. 2005. View Article : Google Scholar : PubMed/NCBI
81	Hawrylewicz EJ, Zapata JJ and Blair WH: Soy and experimental cancer: animal studies. J Nutr. 125:698S–708S. 1995.PubMed/NCBI
82	Linsalata M, Messa C, Russo F, Cavallini A and Di Leo A: Estrogen receptors and polyamine levels in human gastric carcinoma. Scand J Gastroenterol. 29:67–70. 1994. View Article : Google Scholar : PubMed/NCBI
83	Russo F, Linsalata M, Messa C, et al: Polyamines and estrogen-receptor concentrations in human colorectal carcinomas. Ital J Gastroenterol. 24:8–12. 1992.PubMed/NCBI
84	Cross HS, Kallay E, Lechner D, Gerdenitsch W, Adlercreutz H and Armbrecht HJ: Phytoestrogens and vitamin D metabolism: a new concept for the prevention and therapy of colorectal, prostate, and mammary carcinomas. J Nutr. 134:1207S–1212S. 2004.PubMed/NCBI
85	Booth C, Hargreaves DF, Hadfield JA, McGown AT and Potten CS: Isoflavones inhibit intestinal epithelial cell proliferation and induce apoptosis in vitro. Br J Cancer. 80:1550–1557. 1999. View Article : Google Scholar : PubMed/NCBI
86	Li HQ, Luo Y and Qiao CH: The mechanisms of anticancer agents by genistein and synthetic derivatives of isoflavone. Mini Rev Med Chem. 12:350–362. 2012. View Article : Google Scholar : PubMed/NCBI
87	Shon YH, Park SD and Nam KS: Effective chemopreventive activity of genistein against human breast cancer cells. J Biochem Mol Biol. 39:448–451. 2006. View Article : Google Scholar : PubMed/NCBI
88	Linsalata M, Russo F, Notarnicola M, et al: Effects of genistein on the polyamine metabolism and cell growth in DLD-1 human colon cancer cells. Nutr Cancer. 52:84–93. 2005. View Article : Google Scholar : PubMed/NCBI
89	Tanaka T, Makita H, Kawabata K, et al: Chemoprevention of azoxymethane-induced rat colon carcinogenesis by the naturally occurring flavonoids, diosmin and hesperidin. Carcinogenesis. 18:957–965. 1997. View Article : Google Scholar : PubMed/NCBI
90	Au A, Li B, Wang W, Roy H, Koehler K and Birt D: Effect of dietary apigenin on colonic ornithine decarboxylase activity, aberrant crypt foci formation, and tumorigenesis in different experimental models. Nutr Cancer. 54:243–251. 2006. View Article : Google Scholar : PubMed/NCBI
91	Linsalata M, Orlando A, Messa C, Refolo MG and Russo F: Quercetin inhibits human DLD-1 colon cancer cell growth and polyamine biosynthesis. Anticancer Res. 30:3501–3507. 2010.PubMed/NCBI
92	Gosse F, Roussi S, Guyot S, et al: Potentiation of apple procyanidin-triggered apoptosis by the polyamine oxidase inactivator MDL 72527 in human colon cancer-derived metastatic cells. Int J Oncol. 29:423–428. 2006.
93	Ibanez C, Simo C, Garcia-Canas V, Gomez-Martinez A, Ferragut JA and Cifuentes A: CE/LC-MS multiplatform for broad metabolomic analysis of dietary polyphenols effect on colon cancer cells proliferation. Electrophoresis. 33:2328–2336. 2012. View Article : Google Scholar : PubMed/NCBI
94	Wallerath T, Deckert G, Ternes T, et al: Resveratrol, a polyphenolic phytoalexin present in red wine, enhances expression and activity of endothelial nitric oxide synthase. Circulation. 106:1652–1658. 2002. View Article : Google Scholar : PubMed/NCBI
95	Sengottuvelan M, Senthilkumar R and Nalini N: Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim Biophys Acta. 1760:1175–1183. 2006. View Article : Google Scholar
96	Wolter F and Stein J: Resveratrol enhances the differentiation induced by butyrate in caco-2 colon cancer cells. J Nutr. 132:2082–2086. 2002.PubMed/NCBI
97	Schneider Y, Vincent F, Duranton B, et al: Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 158:85–91. 2000. View Article : Google Scholar : PubMed/NCBI
98	Schneider Y, Duranton B, Gosse F, Schleiffer R, Seiler N and Raul F: Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer. 39:102–107. 2001. View Article : Google Scholar : PubMed/NCBI
99	Wolter F, Turchanowa L and Stein J: Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis. 24:469–474. 2003. View Article : Google Scholar : PubMed/NCBI
100	Ulrich S, Loitsch SM, Rau O, et al: Peroxisome proliferator-activated receptor gamma as a molecular target of resveratrol-induced modulation of polyamine metabolism. Cancer Res. 66:7348–7354. 2006. View Article : Google Scholar : PubMed/NCBI
101	Wolter F, Ulrich S and Stein J: Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in colorectal cancer: key role of polyamines? J Nutr. 134:3219–3222. 2004.PubMed/NCBI
102	Henning SM, Wang P, Abgaryan N, et al: Phenolic acid concentrations in plasma and urine from men consuming green or black tea and potential chemopreventive properties for colon cancer. Mol Nutr Food Res. 57:483–493. 2013. View Article : Google Scholar : PubMed/NCBI
103	Yang CS, Li G, Yang Z, Guan F, Chen A and Ju J: Cancer prevention by tocopherols and tea polyphenols. Cancer Lett. Feb 8–2013.(Epub ahead of print).
104	Kumazaki M, Noguchi S, Yasui Y, et al: Anti-cancer effects of naturally occurring compounds through modulation of signal transduction and miRNA expression in human colon cancer cells. J Nutr Biochem. 24:1849–1858. 2013. View Article : Google Scholar
105	Melgarejo E, Urdiales JL, Sanchez-Jimenez F and Medina MA: Targeting polyamines and biogenic amines by green tea epigallocatechin-3-gallate. Amino Acids. 38:519–523. 2010. View Article : Google Scholar : PubMed/NCBI
106	Bachrach U and Wang YC: Cancer therapy and prevention by green tea: role of ornithine decarboxylase. Amino Acids. 22:1–13. 2002. View Article : Google Scholar : PubMed/NCBI
107	Paul B, Hayes CS, Kim A, Athar M and Gilmour SK: Elevated polyamines lead to selective induction of apoptosis and inhibition of tumorigenesis by (−)-epigallocatechin-3-gallate (EGCG) in ODC/Ras transgenic mice. Carcinogenesis. 26:119–124. 2005.PubMed/NCBI
108	Chung JY, Huang C, Meng X, Dong Z and Yang CS: Inhibition of activator protein 1 activity and cell growth by purified green tea and black tea polyphenols in H-ras-transformed cells: structure-activity relationship and mechanisms involved. Cancer Res. 59:4610–4617. 1999.PubMed/NCBI
109	Gupta S, Ahmad N, Marengo SR, MacLennan GT, Greenberg NM and Mukhtar H: Chemoprevention of prostate carcinogenesis by alpha-difluoromethylornithine in TRAMP mice. Cancer Res. 60:5125–5133. 2000.PubMed/NCBI
110	Milovic V, Turchanowa L, Stein J and Caspary WF: Transepithelial transport of putrescine across monolayers of the human intestinal epithelial cell line, Caco-2. World J Gastroenterol. 7:193–197. 2001.PubMed/NCBI
111	Zoumas-Morse C, Rock CL, Quintana EL, Neuhouser ML, Gerner EW and Meyskens FL Jr: Development of a polyamine database for assessing dietary intake. J Am Diet Assoc. 107:1024–1027. 2007. View Article : Google Scholar : PubMed/NCBI
112	Loser C, Eisel A, Harms D and Folsch UR: Dietary polyamines are essential luminal growth factors for small intestinal and colonic mucosal growth and development. Gut. 44:12–16. 1999. View Article : Google Scholar : PubMed/NCBI
113	Seiler N, Sarhan S, Grauffel C, Jones R, Knodgen B and Moulinoux JP: Endogenous and exogenous polyamines in support of tumor growth. Cancer Res. 50:5077–5083. 1990.PubMed/NCBI
114	Muth A, Madan M, Archer JJ, Ocampo N, Rodriguez L and Phanstiel O: Polyamine transport inhibitors: design, synthesis, and combination therapies with difluoromethylornithine. J Med Chem. 57:348–363. 2014. View Article : Google Scholar : PubMed/NCBI
115	Ignatenko NA, Besselsen DG, Roy UK, et al: Dietary putrescine reduces the intestinal anticarcinogenic activity of sulindac in a murine model of familial adenomatous polyposis. Nutr Cancer. 56:172–181. 2006. View Article : Google Scholar : PubMed/NCBI
116	Yerushalmi HF, Besselsen DG, Ignatenko NA, et al: Role of polyamines in arginine-dependent colon carcinogenesis in Apc(Min) (/+) mice. Mol Carcinog. 45:764–773. 2006. View Article : Google Scholar : PubMed/NCBI
117	Gerner EW: Impact of dietary amino acids and polyamines on intestinal carcinogenesis and chemoprevention in mouse models. Biochem Soc Trans. 35:322–325. 2007. View Article : Google Scholar : PubMed/NCBI
118	Ignatenko NA, Gerner EW and Besselsen DG: Defining the role of polyamines in colon carcinogenesis using mouse models. J Carcinog. 10:102011. View Article : Google Scholar : PubMed/NCBI
119	Zell JA, Ignatenko NA, Yerushalmi HF, et al: Risk and risk reduction involving arginine intake and meat consumption in colorectal tumorigenesis and survival. Int J Cancer. 120:459–468. 2007. View Article : Google Scholar : PubMed/NCBI
120	Vargas AJ, Wertheim BC, Gerner EW, Thomson CA, Rock CL and Thompson PA: Dietary polyamine intake and risk of colorectal adenomatous polyps. Am J Clin Nutr. 96:133–141. 2012. View Article : Google Scholar : PubMed/NCBI
121	Raj KP, Zell JA, Rock CL, et al: Role of dietary polyamines in a phase III clinical trial of difluoromethylornithine (DFMO) and sulindac for prevention of sporadic colorectal adenomas. Br J Cancer. 108:512–518. 2013. View Article : Google Scholar : PubMed/NCBI
122	Cipolla BG, Havouis R and Moulinoux JP: Polyamine reduced diet (PRD) nutrition therapy in hormone refractory prostate cancer patients. Biomed Pharmacother. 64:363–368. 2010. View Article : Google Scholar : PubMed/NCBI